Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Names Clarissa Sowemimo-Coker as permanent chief executive officer, effective immediately. She was named interim CEO in December, after having joined the firm over four years ago. Additionally, says its subsidiary Oxford Cannabinoid Technologies Ltd has renewed its Home Office licence, which permits OCT to supply Schedule 1 drugs for research purposes. Adds that progress towards the commencement of phase 1 clinical trial for its lead drug candidate, OCT461201, continues.

CEO Sowemimo-Coker says: ‘I am proud and privileged to be leading the company and our excellent team at such a crucial stage in our development. Our aim is to get our new medicines into the hands of patients who need them as quickly as possible.’

Current stock price: 1.18 pence each, up 7.3% on Wednesday afternoon in London

12-month change: down 7.1%

Copyright 2023 Alliance News Ltd. All Rights Reserved.